FDA Approves Pfizer’s Abrilada, Biosimilar to Humira, for IBD and Other Inflammatory Disorders

FDA Approves Pfizer’s Abrilada, Biosimilar to Humira, for IBD and Other Inflammatory Disorders
Abrilada (adalimumab-afzb), a biosimilar to Humira (adalimumab), has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of seven inflammatory disorders, including adult Crohn's disease and ulcerative colitis, two forms of inflammatory bowel disease (IBD). Pfizer, which developed Abrilada, aims to have the therapy available to U.S. patients in 2023. Abrilada was also approved for rheumatoid arthritispsoriatic arthritisplaque psoriasis, ankylosing spondylitis, and juvenile idiopathic arthritis. Adalimumab is the active ingredient in both Abrilada and Humira. It helps reduce inflammation by targeting and blocking the pro-inflammatory tumor necrosis factor. A biosimilar is a biologic medical product (which means that it is made from living cells rather than by chemical production) that is very similar to
Subscribe or to access all post and page content.